Page 69 - 2024 Taiwan Health and Welfare Report

04 ｜ Health Care

1,197 first generation patients and 687 second Given the global absence of a hepatitis C vaccine,
generation patients. A total of 18,786 Yu Cheng treating hepatitis C patients is the best means of saving
patients received subsidy for outpatient (and lives and reducing transmission. Since 2017, we have
emergency) service copayments, 74 received provided full oral antiviral therapy to hepatitis C patients,
subsidy for their hospitalization, and 562 reducing their economic burden, alleviating treatment
received free health examination. To date, 272 pain, and achieving a higher cure rate. As of December
applications of solatium payments for surviving 2023, this new therapy has treated around 160,000
family members have been approved. patients, with a success rate of nearly 99%. The Health
Promotion Administration of the Ministry of Health and
Section 4 Prevention and Control of HCV
Welfare began offering free hepatitis C screening for
infection individuals born in 1966 or later and aged 45 and above
The Ministry has put forward the "2018-2025 in August 2011. In June 2019, this was expanded to
National Policy Framework for Hepatitis C Elimination" include free screening for indigenous peoples aged 40
with three key policy directions: "Therapy Spear-heads to 60, and in September 2020, it was further extended
Prevention", "Screening Supports Therapy", and to include free screening for the general population aged
"Prevention Secures Outcomes". The aim is to achieve 45 to 79 (indigenous peoples aged 40 to 79). According
the WHO's objective to eliminate hepatitis C by 2025, to the National Hepatitis C Elimination Progress
with targets including diagnosing 90% of chronic Monitoring Information Network (TWNHCP-MIN), as of
hepatitis C patients and treating 80% of them, thus December 2023, the number of screenings for people
reducing their impact as a major public health burden. aged 45 to 79 has reached 5.91 million.

Figure 4-6 Outcome of Rare Disease Care in 2023

Reported 20,916 cases
Announced 243 types of publicly announced rare diseases
of rare diseases
Served 7,694 patients
with rare disease under the Rare Disease Care
Services Plan
Announced 139 types
Subsidized 1,474 patients
of medication for rare diseases
of rare diseases for their treatment and
purchase of special nutritional supplements and
emergency orphan drugs
Announced 80 test items

for rare disease diagnosis Subsidized 1,876 patients
confirmation in Taiwan with rare diseases not covered by the NHI for their
medical expenses

Announced 96 items Approved 10 subsidy programs
and publicly solicit projects for the prevention and
of special nutrition foods for rare treatment of rare diseases (including research,
disease diagnostic testing, treatment, advocacy, etc.).

After reading this article, scan the QR Code.
Please fill-in the questionnaire.
67